CytomX Therapeutics Appoints Dr. Mani Mohindru to Board of Directors
December 22 2020 - 4:05PM
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage
oncology-focused biopharmaceutical company pioneering a novel class
of investigational antibody therapeutics based on its Probody®
technology platform, today announced the appointment of Mani
Mohindru, PhD to the Company’s board of directors. Dr. Mohindru
brings to CytomX deep and varied experience across the life
sciences industry, with particular experience in finance and
corporate strategy.
“We are pleased to welcome Mani to CytomX’s
board of directors,” commented Sean McCarthy, D.Phil., president,
chief executive officer (CEO) and chairman of CytomX. “Mani brings
a unique combination of scientific, financial and strategic acumen
to the board that will prove invaluable as we advance our clinical
pipeline towards multiple significant data updates in 2021 and
execute towards our long-term vision.”
Dr. Mohindru is an experienced biotech executive
with several years of biopharmaceutical industry leadership as well
as Wall Street experience. Most recently she was the CEO of
CereXis, Inc., a biotech company focused on rare tumor indications.
Earlier, she also served as chief financial officer and chief
strategy officer at Cara Therapeutics (Nasdaq: CARA) and chief
strategy officer at Curis, Inc. (Nasdaq: CRIS). Prior to her
leadership roles in the biotechnology industry, Dr. Mohindru spent
many years as an equity research analyst covering the biotechnology
sector at UBS, Credit Suisse and ThinkEquity. She also co-founded a
privately-held biotechnology company and was a healthcare industry
consultant. Currently, she is a member of the board of directors of
SAB Biotherapeutics, a clinical-stage biopharmaceutical company
advancing a new class of immunotherapies. Dr. Mohindru received her
Ph.D. in neurosciences from Northwestern University and her Masters
in biotechnology and BS in human biology (Hons) from the All India
Institute of Medical Sciences, New Delhi, India.
“I am excited to join CytomX’s board as the
Company continues to develop and advance its innovative Probody
platform, which holds the potential to unlock highly effective
cancer therapies by exploiting previously undruggable targets,” Dr.
Mohindru added. “I look forward to leveraging my experiences across
drug development and corporate strategy to help advance the
Company’s leadership in the field of conditional activation of
antibody-drug conjugates and other therapeutic modalities.”
About CytomX TherapeuticsCytomX
is a clinical-stage, oncology-focused biopharmaceutical company
with a vision of transforming lives with safer, more effective
therapies. We are developing a novel class of investigational
antibody therapeutics, based on our Probody® technology platform,
for the treatment of cancer. CytomX has strategic drug discovery
and development collaborations with AbbVie, Amgen, Astellas, and
Bristol Myers Squibb.
Probody therapeutics are designed to remain
inactive until they are activated by proteases in the tumor
microenvironment. As a result, Probody therapeutics are intended to
bind selectively to tumors and decrease binding to healthy tissue,
to minimize toxicity and potentially create safer, more effective
therapies. As leaders in the field, our innovative technology is
designed to turn previously undruggable targets into druggable
targets and to enable more effective combination therapies. CytomX
and its partners, comprised of leading biotechnology and
pharmaceutical companies, have developed a robust pipeline of
potential first-in-class therapeutic candidates against novel,
difficult to drug targets and potential best-in-class
immunotherapeutic candidates against clinically validated targets.
The CytomX clinical-stage pipeline includes first-in-class product
candidates against previously undruggable targets, including a
CD166-targeting Probody drug conjugate wholly owned by CytomX
(CX-2009) and a CD71-targeting Probody drug conjugate partnered
with AbbVie (CX-2029). CD166 and CD71 are among cancer targets that
are considered to be inaccessible to conventional antibody-drug
conjugates due to their presence on many healthy tissues. The
CytomX clinical-stage pipeline also includes cancer
immunotherapeutic candidates against validated targets such as the
CTLA-4-targeting Probody therapeutics, BMS-986249 and BMS-986288,
partnered with Bristol Myers Squibb, and our wholly-owned
anti-PD-L1 Probody therapeutic, CX-072. For additional information
about CytomX Therapeutics, visit www.cytomx.com and follow us on
LinkedIn and Twitter.
CytomX Therapeutics Forward-Looking
Statements
This press release includes forward-looking
statements. Such forward-looking statements involve known and
unknown risks, uncertainties and other important factors that are
difficult to predict, may be beyond our control, and may cause the
actual results, performance or achievements to be materially
different from any future results, performance or achievements
expressed or implied in such statements. Accordingly, you should
not rely on any of these forward-looking statements, including
those relating to the potential benefits, safety and efficacy or
progress of CytomX’s or any of its collaborative partners’ product
candidates, including CX-2009, CX-2029, BMS-986249 and BMS-986288,
the potential benefits or applications of CytomX’s Probody platform
technology, CytomX’s ability to develop and advance product
candidates into and successfully complete clinical trials,
including the ongoing and planned clinical trials of CX-2009,
CX-2029, BMS-986249 and BMS-986288, and the timing of the
commencement of clinical trials and other development milestones.
Risks and uncertainties that contribute to the uncertain nature of
the forward-looking statements include: the unproven nature of
CytomX’s novel Probody Platform technology; CytomX’s clinical trial
product candidates are in the initial stages of clinical
development and its other product candidates are currently in
preclinical development, and the process by which preclinical and
clinical development could potentially lead to an approved product
is long and subject to significant risks and uncertainties,
including the risk that the COVID-19 worldwide pandemic may
continue to negatively impact the business, research and clinical
operations of CytomX or its partners, including the development of
preclinical drug candidates due to delays in and disruption of
research activities and the development of clinical drug candidates
due to delays in or disruption of clinical trials, including
impacts on the enrollment of patients in clinical trials or other
clinical trial disruptions; the possibility that the results of
early clinical trials may not be predictive of future results; the
possibility that CytomX’s clinical trials will not be successful;
the possibility that current preclinical research may not result in
additional product candidates; CytomX’s dependence on the success
of CX-2009, CX-2029, BMS-986249, BMS-986288, and CX-072; CytomX’s
reliance on third parties for the manufacture of the company’s
product candidates; and possible regulatory developments
in the United States and foreign countries. Additional
applicable risks and uncertainties include those relating to our
preclinical research and development, clinical development, and
other risks identified under the heading "Risk Factors" included in
CytomX’s Quarterly Report on Form 10-Q filed with
the SEC on November 5, 2020. The forward-looking
statements contained in this press release are based on information
currently available to CytomX and speak only as of the date on
which they are made. CytomX does not undertake and specifically
disclaims any obligation to update any forward-looking statements,
whether as a result of any new information, future events, changed
circumstances or otherwise.
Probody is a U.S. registered trademark of CytomX
Therapeutics, Inc.
CytomX Contact:Chau Cheng, PhD
MBAVP, Investor Relations & Corp.
Communicationsccheng@cytomx.com650-273-4999
Investor and Media
Contact:Stern Investor RelationsStephanie
Ascherstephanie.ascher@sternir.com212-362-1200
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Sep 2024 to Oct 2024
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Oct 2023 to Oct 2024